RenovoRx, Inc. (RNXT)
| Market Cap | 38.05M -22.9% |
| Revenue (ttm) | 1.49M +520.4% |
| Net Income | -12.27M |
| EPS | -0.33 |
| Shares Out | 45.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 129,582 |
| Open | 0.8550 |
| Previous Close | 0.8646 |
| Day's Range | 0.8407 - 0.8868 |
| 52-Week Range | 0.7006 - 1.4500 |
| Beta | 1.00 |
| Analysts | Strong Buy |
| Price Target | 7.03 (+733.14%) |
| Earnings Date | May 14, 2026 |
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Financial Performance
In 2025, RenovoRx's revenue was $1.12 million, an increase of 2511.63% compared to the previous year's $43,000. Losses were -$11.17 million, 26.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RNXT stock is "Strong Buy." The 12-month stock price target is $7.03, which is an increase of 733.14% from the latest price.
News
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comm...
RenovoRx announces FDA Orphan Drug Designation for oxaliplatin
RenovoRx (RNXT) announced that the FDA recently granted RenovoRx Orphan Drug Designation of oxaliplatin for the treatment of pancreatic cancer. The designation was issued by the FDA’s Office of Orphan...
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity Third FDA Orphan Drug Designation Continues to Advance Re...
RenovoRx announces pharmacokinetic data using TAMP platform
RenovoRx (RNXT) announced that an abstract from a pharmacokinetic and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial has been published online in connection with the 2026 ...
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic ...
RenovoRx Transcript: A.G.P.'s Annual Virtual Healthcare Conference
TAMP technology enables targeted chemotherapy with reduced toxicity, driving strong revenue growth from the RenovoCath device. The pivotal TIGeR-PaC trial is nearing full enrollment, with final data expected in 2027. Ample cash reserves support ongoing commercial and clinical expansion.
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and comme...
RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)
Reports Q1 revenue $563,000, consensus $463,250.
RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M
The company believes its current cash resources are sufficient to fund operations into at least the second half of 2027.
RenovoRx Earnings Call Transcript: Q1 2026
Record Q1 2026 revenue grew 136% sequentially, driven by rapid expansion to 16 active cancer centers and strong repeat orders. Guidance for 2026 revenue remains $3–$4 million, with a robust pipeline and sufficient cash to fund operations into 2027.
RenovoRx Earnings release: Q1 2026
RenovoRx released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
RenovoRx Quarterly report: Q1 2026
RenovoRx has published its Q1 2026 quarterly earnings report on May 14, 2026.
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Thera...
RenovoRx Slides: Investor presentation
RenovoRx has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
RenovoRx Proxy statement: Proxy filing
RenovoRx filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and com...
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
RenovoRx files to sell 8.44M shares of common stock for holders
17:11 EDT RenovoRx (RNXT) files to sell 8.44M shares of common stock for holders
RenovoRx Registration statement: Registration filing
RenovoRx filed a registration statement on April 16, 2026, providing details about a securities offering with the SEC.
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer
RenovoRx secures Japanese patent allowance for targeted drug-delivery
RenovoRx (RNXT) announced that the Japan Patent Office has issued a Notice of Allowance for the company’s first Japanese patent application titled “Method and Apparatus for Delivering an Agent Through...
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
Patent Expands Protection for the Company's RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System RenovoRx Currently Holds a Strong and Growing Global Intellectual Property Portfolio with...
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More
RenovoRx Earnings Call Transcript: Q4 2025
2025 marked the first full year of commercial revenue, with $1.1 million generated and a strong gross margin. The company targets tripling its active sites to 36 in 2026, expects $3–$4 million in revenue, and is well-funded following a $10 million private placement.